Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07738874

Analyzing Retinal Microanatomy in Retinopathy of Prematurity to Improve Care

Retinopathy of prematurity (ROP) is a disorder of development of the retina and its vasculature that can impact vision in vulnerable preterm neonates for a lifetime. A major barrier to improving ROP outcomes is the lack of easy access and low stress means to obtain objective measures of ROP disease severity across the retina in these infants. The long-term goal of this program is to provide information which will improve preterm infant health and vision via objective bedside imaging and analysis that characterizes retina-wide ROP level of disease, its response to treatment and development, and to rapidly translate this for better early intervention and improved future vision care.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

0 day–9 month

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Duke University Eye Center, Durham, North Carolina, United States

Loading trial locations.

About this study

Retinopathy of prematurity (ROP) remains the leading cause of childhood blindness in the US and other developed countries, blinding 150,000-200,000 children worldwide annually and leaving many more visually impaired. This vision loss is lifelong and impacts neurodevelopment. While current treatments including the addition of anti-VEGF therapies decrease the likelihood of severe vision loss from ROP, these benefits have come with a burden of monitoring for recurrence, added to the widespread task of monitoring for onset of treatment requiring ROP. This is a global issue, as the improved survival of younger preterm infants increases the burden of care in a world where there is a worsening shortage of experts for bedside ROP exams.

A major barrier to improving ROP management and outcomes is the lack of easy access to incisive, objective measures of ROP disease severity, especially at critical junctures for referral or treatment, response to treatment and reactivation without causing infant stress in the nursery. ROP monitoring by standard care exam and handheld widefield photographs (e.g., RetCam by Natus) use white light, are stressful to the infant, and are repeated more often in more premature infants and with more severe ROP; their induced stress can contribute to poorer neurodevelopment. Drawing/scores of an exam are subjective, and Retcam photos are limited by loss of view from areas of shadow, worse in eyes with dark pigmentation or vitreous haze, and from avoidance response in infants, especially after term age when ROP retreatment decisions must be made. These may contribute to expert disagreement on ROP disease severity based on such photos. AI-generated models are often based on curated sets of good quality images which do not reflect real-world, lower-quality photos.

With the newest generation of handheld OCTs, a field-of-view wider than ROP photographs is possible, as the researchers have established for the proposed renewal. In the current grant period, they have established that with high speed swept-source OCT imaging of a smaller field-of-view, they can obtain: OCT images of good contrast that are agnostic to fundus pigmentation, less infant stress due to lack of visible light, vascular views further into the margin of the imaging field due to coherence gating inherent to OCT, and reproducible depth-resolved retinal measures of risk (e.g. choroid) for treatment requiring disease and of neovascularization, regression and traction at the vascular-avascular junction. Multiple research groups have studied OCT imaging in preterm infants, but rigorous studies to classify ROP on OCT relative to standard care classification are rare. Without such translation, there is a risk that with the use of OCT images physicians will overtreat features, rather than treating ROP at severity levels based on clinical trial evidence. The proposed study will provide clinician-scientists with more objective and precise OCT-based measures of level of severity within (and relative to) current ROP classification.

Having completed the necessary groundwork, the investigators are prepared to test our hypotheses and validate OCT-based measures for referral warranted (RW) and treatment requiring (TR)-ROP. The researchers will demonstrate through measures of infant stress, scalable grading and AI tools, the basis for OCT imaging use to improve ROP care.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Health care provider, knowledgeable of protocol, agrees that study personnel could contact the Parent/Legal guardian
  • Parent/Legal Guardian is able and willing to consent to study participation for the infant
  • Infant meets the American Association of Pediatrics eligibility of ROP screening, and is age < 35 weeks postmenstrual age at first visit
  • Infants transferred to nursery for ROP treatment (some participants)

Exclusion criteria

  • Participant or Parent/Legal Guardian unwilling or unable to provide consent
  • Adult participant or infant/child has a health or eye condition that preclude eye examination or retinal imaging (e.g. corneal opacity such as with Peter's anomaly or cataract)
  • Infant has a health condition, other than prematurity, that has a profound impact on brain development (e.g. anencephaly)

Treatment and study plan

Ultra-widefield Optical Coherence Tomography (UWF-OCT)

Device

Handheld retinal OCT imaging at the bedside or in clinic with an ultra-widefield handheld optical coherence tomography

Other names: optical coherence tomography

Wide-field ophthalmic imaging system

Device

Handheld wide-field ophthalmic fundus imaging at the bedside or in clinic

Primary outcomes

  1. Sensitivity and specificity of ultra-widefield OCT vs bionocular indirect ophthalmoscopy or fundus photograph to identify referral-warranted retinopathy of prematurity

    Time frame: Up to 60 weeks post-menstrual age

    OCT markers that determine the presence or absence of referral-warranted retinopathy of prematurity.

  2. Measurement of infant stress

    Time frame: Up to 60 weeks post-menstrual age

    Assessment of stress and discomfort using modified CRIES score (crying 0-4; facial expression 0-2; heart rate beats per minute; change in respiratory support) during each eye imaging and compared to baseline pre-imaging score adverse events recorded during imaging (bradycardia, tachycardia, desaturation, emesis, and ocular adverse events e.g. conjunctival hemorrhage)

Secondary outcomes

  1. Retinal thickness at the fovea and surrounding optic nerve as measured by OCT reading

    Time frame: Up to 9 months corrected age

    Retinal thickness (microns) at the fovea and surrounding optic nerve.

  2. Artificial Intelligence algorithms to classify ROP

    Time frame: Up to 60 weeks post-menstrual age

    Development of clinician-in-the-loop AI-based ROP classification algorithm for OCT imaging

  3. ROP vascular severity score

    Time frame: Up to 9 months corrected age

    Scale of 1-9 based on retinal vessel dilation and tortuosity

  4. ROP severity as determined by clinical exam

    Time frame: Up to 9 months corrected age

    Clinical determination of the presence and/or severity of retinal vessel tortuosity, aggressive ROP, extra retinal neovascularization, shunt vessels, vitreous opacities, vitreous haze, retinoschisis and retinal detachment

  5. ROP severity as determined by retinal photo reading

    Time frame: Up to 9 months corrected age

    Presence and/or severity of retinal vessel tortuosity, aggressive ROP, extra retinal neovascularization, shunt vessels, vitreous opacities, vitreous haze, retinoschisis and retinal detachment as determined by fundus photograph grading

  6. ROP severity as determined by OCT reading

    Time frame: Up to 9 months corrected age

    Presence and/or severity of: retinal vessel tortuosity, vascular abnormality score by OCT (VASO), aggressive ROP, extra retinal neovascularization, vitreous abnormalities, shunt vessels,retinoschisis and retinal detachment as determined by OCT grading.

Study contacts

Contact information is provided by the study sponsor or research team.

Michelle N McCall, MCAPM, BA

CONTACT

[email protected]

919-684-0544

Xi Chen, MD

CONTACT

[email protected]

919-684-8434

Sponsors and collaborators

Lead sponsor

Duke University

Other

Collaborators

  • National Eye Institute (NEI)
  • University of Pennsylvania

Registry information

Official study title

Analyzing Retinal Microanatomy in Retinopathy of Prematurity to Improve Care 3 (BabySTEPS3)

Acronym: (BabySTEPS3)

Important dates

Study start
2026
Primary completion
2031
Study completion
2031
First posted
Jul 31, 2026
Registry last updated
Jul 31, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.